Skip to main content

Diabetes Expert Insights

Pharmacy Learning Network
By Julie Gould Julie Lauffenburger, PharmD, Harvard Medical School and division of Pharmacoepidemiology and Pharmacoeconomics at the Brigham and Women’s Hospital, explains how more intensive insulin-adherence interventions impact patient outcomes and highlights the challenges faced when…
Pharmacy Learning Network
The answer may be yes. Diabetes mellitus has reached panepidemic proportions across the world with approximately 382 million people diagnosed and is set to rise to 592 million by 2040.1 In 2013, half of all premature deaths in adults under the age of 60 were attributable to diabetes. Another 175…
Pharmacy Learning Network
Statins along with aspirin and inhibitors of the renin-angiotensin-renin system are foundational to the treatment of atherosclerotic cardiovascular disease. The National Health and Nutrition Examination Study or NHANES reported that in 2011-2012, 23% of adults over the age of 40 reported using a…
Pharmacy Learning Network
Gestational diabetes (GD) was previously considered the onset of diabetes during pregnancy in patients that have never been diagnosed before the pregnancy. This meant that women tested at any time (first, second, or third trimester) were diagnosed as having GD. However, in the past few years, the…
Pharmacy Learning Network
Incretin based therapies (IBT) continue to grow in popularity as a preferred treatment option for people with type 2 diabetes (T2D). However, it is still common to find confusion between the 2 classes of drugs included in the IBT category. Glucagon-like peptide -1 (GLP1) agonists and dipeptidyl…
Back to Top